20 studies found for:    MAOA
Show Display Options
Rank Status Study
1 Active, not recruiting Evaluation of Moclobemide, a Reversible MAO-A Inhibitor, as an Adjunct to Nicotine Replacement Therapy in Female Smokers
Condition: Nicotine Dependence
Interventions: Drug: Nicotine Patch;   Drug: Moclobemide
2 Recruiting Phenelzine Sulfate and Docetaxel in Treating Patients With Prostate Cancer With Progressive Disease After First-Line Therapy With Docetaxel
Conditions: Adenocarcinoma of the Prostate;   Hormone-resistant Prostate Cancer;   Recurrent Prostate Cancer
Interventions: Drug: docetaxel;   Procedure: prostate biopsy;   Other: laboratory biomarker analysis;   Drug: phenelzine sulfate
3 Recruiting Harmonized AS/MQ Efficacy Study - Thailand
Condition: Malaria
Intervention: Drug: Artesunate/mefloquine (AS/MQ)
4 Completed Monoamine Oxidases in Smoking Pregnant Women and Newborns
Conditions: Smoking;   Pregnancy;   Newborn
Intervention:
5 Unknown  Serotonergic System and Violent Video Games
Condition: Healthy Volunteers
Intervention: Drug: cipralex
6 Completed Physiological, Cognitive and Cerebral Activity Changes as a Function of Cigarette Smoking (With or Without Nicotine) and Tobacco Abstinence
Condition: Smoking Cessation
Intervention:
7 Completed Survey of Adolescent Living in Vestmanland
Conditions: Alcohol Abuse;   Criminalism;   Depression
Intervention:
8 Terminated
Has Results
PET Biomarkers in Treatment Resistant Depression
Condition: Major Depressive Disorder
Intervention: Drug: tranylcypromine
9 Recruiting Open Label Pharmacokinetic-Pharmacogenetic Study on Polymorphisms in the Organic Cation Transporter OCT1
Conditions: Drug Metabolism;   Membrane Transport
Interventions: Drug: Drug application Amitriptyline;   Drug: Drug application Desvenlafaxine;   Drug: Drug application Sumatriptan;   Drug: Drug application Proguanil
10 Terminated SNAP 25 Gene Study
Condition: Attention-Deficit/Hyperactivity Disorder
Intervention:
11 Recruiting Structural and Functional Connectivity of Frontostriatal and Frontoparietal Networks as Endophenotypes of ADHD
Condition: Attention Deficit/Hyperactivity Disorder
Intervention:
12 Unknown  Effects of Chocolate on Motor Symptoms of Parkinson's Disease
Condition: Parkinson's Disease
Intervention: Dietary Supplement: Chocolate
13 Completed Metoclopramide as Treatment of Clozapine-induced Hypersalivation
Condition: Clozapine-induced Hypersalivation
Interventions: Drug: Metoclopramide;   Drug: placebo
14 Recruiting The Effects of Oral Appliance Therapy on Masseter Muscle Activity in Obstructive Sleep Apnea
Condition: Obstructive Sleep Apnea
Intervention: Device: mandibular advancement appliance
15 Unknown  Safety and Efficacy of Exenatide Injection in Subjects With Type 2 Diabetes Mellitus
Condition: Type 2 Diabetes Mellitus
Intervention: Drug: Exenatide, Placebo
16 Recruiting Safety and Efficacy of AVP-923 in the Treatment of Levodopa-induced Dyskinesia in Parkinson's Disease Patients
Conditions: Dyskinesia;   Parkinson's Disease
Interventions: Drug: AVP-923-45;   Drug: Placebo
17 Recruiting Phase 2 Study to Evaluate LUM001 in Combination With Ursodeoxycholic Acid in Patients With Primary Biliary Cirrhosis
Conditions: Primary Biliary Cirrhosis;   PBC
Interventions: Drug: LUM001;   Drug: Placebo;   Drug: Ursodeoxycholic Acid
18 Recruiting Study of Non-surgical Treatment Versus Observation in Asian Children With Intermittent Exotropia
Condition: Intermittent Exotropia
Intervention: Procedure: Non surgical therapy
19 Recruiting Efficacy of Gabapentin in Prevention of Tourniquet Pain and Hypertension
Conditions: Tourniquet-induced Pain;   Tourniquet-induced Hypertension
Interventions: Drug: gabapentin 600 mg po;   Drug: Placebo pill given one hour before surgery
20 Not yet recruiting Phase I/II Study of Nilotinib/Ruxolitinb Therapy for TKI Resistant Ph-Leukemia
Conditions: Chronic Phase Chronic Myeloid Leukemia;   Accelerated Phase Chronic Myeloid Leukemia;   Blastic Phase Chronic Myeloid Leukemia;   Philadelphia Positive Acute Lymphoblastic Leukemia;   Resistant to Tyrosine Kinase Inhibitor Therapy
Interventions: Drug: Nilotinib;   Drug: Ruxolitinib

Indicates status has not been verified in more than two years